Epiminder Ltd.ASX: EPI

100th patient enrolled in US study ahead of schedule

· Issued by Epiminder Ltd. via ASX

Filed with ASX · · 3 pages · English

Summary by 6ix AI

The study aims to gather evidence on how continuous EEG monitoring can enhance clinical decision-making for patients whose previous EEG assessments were inconclusive. This milestone reflects strong enrollment momentum across multiple epilepsy centers in the United States.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

On 6ix: 6ix.com/news/100th-patient-enrolled-in-us-study-ahead-of-schedule-1

Release

Strong momentum as 100th Patient enrolled ahead of schedule in US DETECT Study Highlights: • Epiminder has enrolled the 100th participant in DETECT, its prospective, randomised, controlled, blinded, multi-centre US study of the Minder System, bringing the study to nearly half of its planned...

Epiminder Ltd. on 6ix

Earlier from Epiminder

Later from Epiminder

All Epiminder news releases